Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Do

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 3, 2016
Idelalisib for treatment of B-cell malignanciesBryan Do, Morgan Mace, Amber Rexwinkle
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 15, 2024
Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphomaJessie Lu, Bryan Do, Brian Primeaux
Hematological Oncology|September 28, 2024
Characterizing second line and beyond therapies for primary central nervous system lymphomasBrian Primeaux, Chelsea Luo, Erin K Yeung, et al.
Pharmacotherapy|January 13, 2017
Chimeric Antigen Receptor T Cells in Hematologic MalignanciesBrandon R Shank, Bryan Do, Adrienne Sevin, et al.
Cancer Treatment and Research Communications|September 15, 2019
Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myelomaMichael J Buege, Bryan Do, Hans C Lee, et al.
British Journal of Haematology|July 18, 2020
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experienceKatharine L Lewis, Collin K Chin, Kate Manos, et al.
Blood Advances|July 10, 2020
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphomaPaolo Strati, Sairah Ahmed, Partow Kebriaei, et al.
Cancer|June 29, 2016
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphomaDai Chihara, Jason R Westin, Yasuhiro Oki, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 3, 2016
Idelalisib for treatment of B-cell malignanciesBryan Do, Morgan Mace, Amber Rexwinkle
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 15, 2024
Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphomaJessie Lu, Bryan Do, Brian Primeaux
Hematological Oncology|September 28, 2024
Characterizing second line and beyond therapies for primary central nervous system lymphomasBrian Primeaux, Chelsea Luo, Erin K Yeung, et al.
Pharmacotherapy|January 13, 2017
Chimeric Antigen Receptor T Cells in Hematologic MalignanciesBrandon R Shank, Bryan Do, Adrienne Sevin, et al.
Cancer Treatment and Research Communications|September 15, 2019
Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myelomaMichael J Buege, Bryan Do, Hans C Lee, et al.
British Journal of Haematology|July 18, 2020
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experienceKatharine L Lewis, Collin K Chin, Kate Manos, et al.
Blood Advances|July 10, 2020
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphomaPaolo Strati, Sairah Ahmed, Partow Kebriaei, et al.
Cancer|June 29, 2016
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphomaDai Chihara, Jason R Westin, Yasuhiro Oki, et al.
Pageof 1